Patents by Inventor Esther BERNALDO DE QUIRÓS PLAZA

Esther BERNALDO DE QUIRÓS PLAZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR OBTAINING REGULATORY T CELLS DERIVED FROM THYMIC TISSUE AND USE OF SAID CELLS AS CELL IMMUNOTHERAPY IN IMMUNE SYSTEM DISORDERS
    Publication number: 20220306990
    Abstract: The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.
    Type: Application
    Filed: March 1, 2019
    Publication date: September 29, 2022
    Inventors: Rafael CORREA ROCHA, Marjorie PION, Esther BERNALDO DE QUIRÓS PLAZA
  • METHOD FOR OBTAINING REGULATORY T CELLS DERIVED FROM THYMIC TISSUE AND USE OF SAID CELLS AS CELL IMMUNOTHERAPY IN IMMUNE SYSTEM DISORDERS
    Publication number: 20210040450
    Abstract: The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.
    Type: Application
    Filed: March 1, 2019
    Publication date: February 11, 2021
    Applicant: Fundaciön Para la Investigaciön Biomédica del Hospital Gregorio Marañón
    Inventors: Rafael CORREA ROCHA, Marjorie PION, Esther BERNALDO DE QUIRÓS PLAZA